Patrick Hsu is Co-Founder of the Arc Institute and Assistant Professor of Bioengineering and Deb Faculty Fellow in the College of Engineering at the University of California, Berkeley. A pioneer in the field of CRISPR gene editing, Patrick's work aims to accelerate scientific progress through innovation in biotechnology development, science funding (Fast Grants), and research institutions (Arc Institute). His research group at Arc and Berkeley works at the intersection of biology and AI to develop technologies for biological programming and design. They recently reported inventions for programmable RNA perturbation, gene writing with DNA recombinases, point-of-care diagnostic tests, and biological foundation models.At the Broad Institute and Harvard University, Patrick conducted some of the first studies of CRISPR-Cas9 genome editing in human cells. As part of the initial team at Editas Medicine, a clinical-stage gene editing company, he also built a drug development team to translate CRISPR tools for treating human genetic disorders. Patrick started his independent academic lab as a Salk-Helmsley Faculty Fellow at the Salk Institute before joining UC Berkeley as a faculty member in the Department of Bioengineering. Patrick has been recognized by the MIT Technology Review's Innovators Under 35, the Amgen Young Investigator Award, Forbes' 30 Under 30, the NIH Early Independence Award, Berkeley Engineering's Deb Faculty Fellowship, the Rainwater Prize for Innovative Early-Career Scientist, and the Rose Hill Innovator Award. He is a co-founder of multiple biotech companies focused on genetic medicines, and is an inventor on 100+ patents and patents pending.